Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
77 studies found for:    SCHIZOPHRENIA 1
Show Display Options
Rank Status Study
1 Recruiting Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
Condition: SCHIZOPHRENIA 1 (Disorder)
Intervention: Drug: fluvoxamine
2 Enrolling by invitation A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
3 Withdrawn Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
Conditions: Bipolar 1 Disorder;   Schizophrenia;   Mental Disorder;   Nervous System Diseases
Interventions: Drug: Aripiprazole;   Device: Ingestible Event Marker (IEM)
4 Completed Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
Conditions: Bipolar 1 Disorder;   Schizophrenia;   Mental Disorder;   Nervous System Disorders
5 Completed Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Conditions: Schizophrenia;   Chinese Han People
6 Completed Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Conditions: Schizophrenia;   Chinese Han People
7 Terminated Imaging Cannabinoid CB1 Receptors in Schizophrenia
Condition: Schizophrenia
8 Active, not recruiting Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.;   Drug: PP3M 263 mg eq.;   Drug: PP3M 350 mg eq.;   Drug: PP3M 525 mg eq.;   Drug: Placebo (20% Intralipid);   Drug: PP1M 50 mg eq.;   Drug: PP1M 75 mg eq.;   Drug: PP1M 100 mg eq.;   Drug: PP1M 150 mg eq.
9 Not yet recruiting Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
Conditions: Schizophrenia;   Mental Disorder;   Nervous System Diseases
Intervention: Device: MIND1 System
10 Recruiting Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
Conditions: Obesity;   Metabolic Syndrome X;   Drug-induced Obesity;   Schizophrenia
Interventions: Drug: Exenatide;   Drug: Placebo
11 Recruiting DAAOI-1 Treatment for Treatment-resistant Schizophrenia
Condition: Schizophrenia
Interventions: Drug: DAAOI-1;   Drug: placebo
12 Completed GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
Conditions: Schizophrenia;   Treatment Refractory
Interventions: Drug: GlyT-1 inhibitor-1;   Drug: Placebo
13 Completed Serotonin 1A Agonists and Cognition in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: adjunctive treatment with buspirone;   Drug: placebo
14 Completed
Has Results
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Asenapine 3x5mg followed by 1x15mg;   Drug: Asenapine 1x15mg followed by 3x5mg
15 Unknown  Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype
Condition: Schizophrenia
Interventions: Drug: Lexapro;   Drug: Cymbalta;   Drug: Placebo
16 Completed Schizophrenia and Physical Exercise
Condition: Schizophrenia
Interventions: Other: Physical Exercise;   Other: Control
17 Completed Clinical Symptoms of Schizophrenia and Physical Exercise
Condition: Schizophrenia
Interventions: Other: Resistance Training;   Other: Concurrent Training;   Other: Control
18 Active, not recruiting Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: DAR-100A;   Drug: Placebo
19 Recruiting Translational Neuroscience Optimization of GlyT1 Inhibitor
Condition: Cognitive Impairments Associated With Schizophrenia
Interventions: Drug: PF-03463275;   Drug: Placebo
20 Completed Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
Condition: Schizophrenia
Intervention: Drug: GSK1018921

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years